FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308584552> ?p ?o ?g. }

• W4308584552 endingPage "105" @default.
• W4308584552 startingPage "94" @default.
• W4308584552 abstract "Background. For many years the primary aim of treatment strategy for ph-negative myeloproliferative neoplasms has been to restrain disease progression, with lasting relief and management of symptoms to improve patients’ quality of life. Generally, this did not lead to a significant increase in life expectancy with primary myelofibrosis and didn’t decrease the risk of fibrosis in patients with polycythemia vera and essential thrombocythemia. To date a new class of targeted drugs has been developed, it is JAK2 inhibitors with pathogenetic effects. The results of clinical trials showed the high efficacy of the first registered drug of this its kind – ruxolitinib – that includes a faster reduction in the symptoms of tumor intoxication and in symptoms associated with the development of splenomegaly and increase in the overall survival rates. It is known that the data obtained during clinical trials of medicines may differ from the results obtained in routine clinical practice. In actual practice drugs are used in a much wider heterogeneous population of patients, less limited first of all by age and comorbid characteristics. It is possible to analyze cohorts of patients including a larger number of clinical cases with a longer follow-up period. In this regard of great interest is the actual clinical experience of long-term use of ruxolitinib in patients whose set is limited only by clinical contraindications for prescribing the drug.Aim. To present our own actual experience of targeted therapy of myelofibrosis and compare the results obtained with the data of clinical trials.Materials and methods. Our analysis includes data from 141 patients (67 (47.5 %) men and 74 (52.5 %) women) in a chronic phase myelofibrosis. All patients received ruxolitinib. Of these, 109 (69 %) patients had primary myelofibrosis, 26 (16 %) – postpolycythemia myelofibrosis, 6 (4 %) – postessential thrombocythemia myelofibrosis. The median age at the start of therapy was 62 (18–84) years. The median disease duration before ruxolitinib was prescribed – 79 (1–401) months. According to the dIpSS (dynamic International prognostic Scoring System) criteria, 13 % of patients were assigned to the low risk group, 38 % – to the intermediate-1, 36 % – to the intermediate-2, 13 % – to the high risk group. Most patients (52 %) had grade 3 bone marrow fibrosis.Results. The median duration of treatment was 18 (range from 1 to 115) months. Symptoms of intoxication were relieved 74 (81 %) of 91 patients, the spleen size decreased in 81 % of patients (the spleen size returned to normal in 25 % of patients). The increase in the median hemoglobin level was 15 %. The proportion of patients requiring blood transfusion decreased by 4 times (from 39 to 9 %). Mean platelet levels normalized in most patients with baseline high and low platelet levels. A complete clinical and hematological response was achieved in 16 % (n = 23) of cases, a partial response – in 26 % (n = 37) of cases, clinical improvement – in 21 % (n = 30), disease stabilization – in 33 % (n = 46) of cases. No response was received in 1 (1 %) patient and in 3 (3 %) cases there was progression of the disease. At the time of analysis, 81 (57 %) of 141 patients were continuing the ruxolitinib treatment. The fatal outcome in 33 (22 %) patients was associated with concomitant diseases, among which 20 (14 %) died from proven COvId-19 infection. Overall survival: 1-year 81 %, 2-year 73 %, 5-year 50 %. Overall survival excluding deaths due to COvId-19: 1-year 92 %, 2-year 85 %, 5-year 70 %. Massive splenomegaly and a high degree of fibrosis were unfavorable predictors of prognosis of overall survival.Conclusion. Target therapy with Janus kinase inhibitor ruxolitinib has demonstrated high efficacy in patients with myelofibrosis in routine clinical practice. The most rapid effect ruxolitinib had on the spleen size and the symptoms of intoxication. Tolerability of ruxolitinib therapy was generally satisfactory. The overall and progression-free survival rates in patients with myelofibrosis, receiving ruxolitinib in the clinical setting was consistent with the results of international multicenter clinical trials." @default.
• W4308584552 created "2022-11-12" @default.
• W4308584552 creator A5011470882 @default.
• W4308584552 creator A5016974799 @default.
• W4308584552 creator A5025597615 @default.
• W4308584552 creator A5030091320 @default.
• W4308584552 creator A5035629448 @default.
• W4308584552 creator A5047009720 @default.
• W4308584552 creator A5071809163 @default.
• W4308584552 creator A5074838105 @default.
• W4308584552 creator A5085541587 @default.
• W4308584552 date "2022-11-06" @default.
• W4308584552 modified "2023-10-01" @default.
• W4308584552 title "Possibilities of targeted therapy for myelofibrosis: Moscow experience" @default.
• W4308584552 cites W2093724620 @default.
• W4308584552 cites W2108585990 @default.
• W4308584552 cites W2121743767 @default.
• W4308584552 cites W2126532431 @default.
• W4308584552 cites W2130983069 @default.
• W4308584552 cites W2326795317 @default.
• W4308584552 cites W2339658711 @default.
• W4308584552 cites W2405712018 @default.
• W4308584552 cites W2418937816 @default.
• W4308584552 cites W2438818779 @default.
• W4308584552 cites W2560688864 @default.
• W4308584552 cites W2589237569 @default.
• W4308584552 cites W2765819988 @default.
• W4308584552 cites W3100579423 @default.
• W4308584552 cites W3163223154 @default.
• W4308584552 cites W3178904653 @default.
• W4308584552 cites W3213534400 @default.
• W4308584552 doi "https://doi.org/10.17650/1818-8346-2022-17-4-94-105" @default.
• W4308584552 hasPublicationYear "2022" @default.
• W4308584552 type Work @default.
• W4308584552 citedByCount "0" @default.
• W4308584552 crossrefType "journal-article" @default.
• W4308584552 hasAuthorship W4308584552A5011470882 @default.
• W4308584552 hasAuthorship W4308584552A5016974799 @default.
• W4308584552 hasAuthorship W4308584552A5025597615 @default.
• W4308584552 hasAuthorship W4308584552A5030091320 @default.
• W4308584552 hasAuthorship W4308584552A5035629448 @default.
• W4308584552 hasAuthorship W4308584552A5047009720 @default.
• W4308584552 hasAuthorship W4308584552A5071809163 @default.
• W4308584552 hasAuthorship W4308584552A5074838105 @default.
• W4308584552 hasAuthorship W4308584552A5085541587 @default.
• W4308584552 hasBestOaLocation W43085845521 @default.
• W4308584552 hasConcept C126322002 @default.
• W4308584552 hasConcept C133925201 @default.
• W4308584552 hasConcept C143998085 @default.
• W4308584552 hasConcept C159110408 @default.
• W4308584552 hasConcept C177713679 @default.
• W4308584552 hasConcept C2776112149 @default.
• W4308584552 hasConcept C2778837598 @default.
• W4308584552 hasConcept C2779134260 @default.
• W4308584552 hasConcept C2779951463 @default.
• W4308584552 hasConcept C2780007613 @default.
• W4308584552 hasConcept C2780076729 @default.
• W4308584552 hasConcept C2781057849 @default.
• W4308584552 hasConcept C2781107747 @default.
• W4308584552 hasConcept C2908647359 @default.
• W4308584552 hasConcept C535046627 @default.
• W4308584552 hasConcept C71924100 @default.
• W4308584552 hasConcept C99454951 @default.
• W4308584552 hasConceptScore W4308584552C126322002 @default.
• W4308584552 hasConceptScore W4308584552C133925201 @default.
• W4308584552 hasConceptScore W4308584552C143998085 @default.
• W4308584552 hasConceptScore W4308584552C159110408 @default.
• W4308584552 hasConceptScore W4308584552C177713679 @default.
• W4308584552 hasConceptScore W4308584552C2776112149 @default.
• W4308584552 hasConceptScore W4308584552C2778837598 @default.
• W4308584552 hasConceptScore W4308584552C2779134260 @default.
• W4308584552 hasConceptScore W4308584552C2779951463 @default.
• W4308584552 hasConceptScore W4308584552C2780007613 @default.
• W4308584552 hasConceptScore W4308584552C2780076729 @default.
• W4308584552 hasConceptScore W4308584552C2781057849 @default.
• W4308584552 hasConceptScore W4308584552C2781107747 @default.
• W4308584552 hasConceptScore W4308584552C2908647359 @default.
• W4308584552 hasConceptScore W4308584552C535046627 @default.
• W4308584552 hasConceptScore W4308584552C71924100 @default.
• W4308584552 hasConceptScore W4308584552C99454951 @default.
• W4308584552 hasIssue "4" @default.
• W4308584552 hasLocation W43085845521 @default.
• W4308584552 hasOpenAccess W4308584552 @default.
• W4308584552 hasPrimaryLocation W43085845521 @default.
• W4308584552 hasRelatedWork W2111123136 @default.
• W4308584552 hasRelatedWork W2602189135 @default.
• W4308584552 hasRelatedWork W2612296054 @default.
• W4308584552 hasRelatedWork W2768585710 @default.
• W4308584552 hasRelatedWork W2801783663 @default.
• W4308584552 hasRelatedWork W2943127363 @default.
• W4308584552 hasRelatedWork W2957228011 @default.
• W4308584552 hasRelatedWork W2995042029 @default.
• W4308584552 hasRelatedWork W3030576992 @default.
• W4308584552 hasRelatedWork W4246545933 @default.
• W4308584552 hasVolume "17" @default.
• W4308584552 isParatext "false" @default.
• W4308584552 isRetracted "false" @default.
• W4308584552 workType "article" @default.